Clinical Trial Update: A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation [Phase 2]

View source ↗

Summary

A pivotal Phase 2 study evaluating HQP1351 in chronic myeloid leukemia in accelerated phase with T315I mutation; current status not provided.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• HQP1351

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: Chronic Myeloid Leukemia - Accelerated Phase | Phase 2 | Status: UNKNOWN